A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

341

Participants

Timeline

Start Date

September 10, 2019

Primary Completion Date

July 31, 2024

Study Completion Date

October 31, 2024

Conditions

Moderately to Severely Active Ulcerative Colitis

Interventions

DRUG

Etrasimod

Drug:Etrasimod Tablet other name:APD334

DRUG

Placebo

Drug:placebo Tablet

Trial Locations (1)

The First Affiliated Hospital of Fourth Military Medical University, PLA, Xi’an